The in vitro diagnostics industry has been at the forefront of the fight against SARS-CoV-2 and medicine’s response to cases of severe COVID-19 disease.
In the February issue of Pathology in Practice, Mark Reed from Pro-Lab Diagnostics provides a commercial perspective and overview of the unprecedented times experienced over the past 12 months.
In addition, Doris-Ann Williams, the British In Vitro Diagnostics Association (BIVDA) Chief Executive, discusses how IVDs will be regulated in a newly independent UK after being regulated under the IVD Directive for the past 20 years, and the effects this may have on industry and clinical laboratories in the UK.
Access the February digital issue here.